OCSE:ORPHA (Denmark)  
Orphazyme AS logo

Orphazyme AS

kr 1.65 (0%) Aug 16
P/E:
At Loss
P/B:
6.16
Market Cap:
kr 58.09M ($ 7.95M)
Enterprise V:
kr -4.20M ($ -575.00K)
Volume:
18.12K
Avg Vol (2M):
80.45K
Also Trade In:
Volume:
18.12K
Market Cap kr:
58.09M
Market Cap $:
7.95M
PE Ratio:
At Loss
Avg Vol (2-Month):
80.45K
Enterprise Value kr:
-4.20M
Enterprise Value $:
-575.00K
PB Ratio:
6.16
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).
Name Current Vs Industry Vs History
Cash-To-Debt 2.56
Equity-to-Asset 0.05
Debt-to-Equity 4.28
Debt-to-EBITDA -0.07
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -28.28
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 14.8
9-Day RSI 26.72
14-Day RSI 34.65
6-1 Month Momentum % -87.09
12-1 Month Momentum % -94.62

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.23
Quick Ratio 1.23
Cash Ratio 0.79
Days Sales Outstanding 280.22

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -20.6
Name Current Vs Industry Vs History
Operating Margin % -1749.79
Net Margin % -1731.11
ROE % -235.95
ROA % -132.02
ROIC % -672.1
ROC (Joel Greenblatt) % -4454.36
ROCE % -206.34

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.59
PB Ratio 6.16
Price-to-Tangible-Book 7.83
EV-to-Revenue -0.11

Financials (Next Earnings Date:2022-09-20)

OCSE:ORPHA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 36.193
EPS (TTM) (kr) -17.94
Beta 1.69
Volatility % 61.69
14-Day RSI 34.65
14-Day ATR (kr) 0.112328
20-Day SMA (kr) 1.7879
12-1 Month Momentum % -94.62
52-Week Range (kr) 1.1 - 40.72
Shares Outstanding (Mil) 35.31

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Orphazyme AS Filings

Document Form Filing Date
No Filing Data